Bipolar Disorder or Schizophrenia |
1.43 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 TMEM180 |
Depressed Affect (Nagel 2018) |
1.45 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 NCAM1 |
Intelligence (Savage-Jansen 2018) |
1.28 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NAT6 |
Schizophrenia (2018) |
1.66 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 TMEM180 |
Worry (Nagel 2018) |
3.96 |
5 |
1 |
2.2 |
0.79 |
1.1e-01 |
C10orf32 CADM2 PRPS1P2 STX1B TMEM180 |
Irritable Bowel Disease (IBD) |
1.55 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
C6orf3 |
Ulcerative Colitis (UC) |
2.03 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
C6orf3 NAT6 |
Reaction Time |
2.67 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ATXN2 COMMD7 |
Age at First Birth |
1.77 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NAT6 |
Body Mass Index (BMI) (2010) |
2.90 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
MAP2K5 NPC1 |
Coronary Artery Disease (CAD) |
1.52 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 |
HbA1C |
1.55 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 |
LDL Cholesterol |
1.21 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ATXN2 |
Lupus |
1.74 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 STX1B |
Primary Biliary Cirrhosis |
1.57 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 |
Schizophrenia (2014) |
1.52 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 TMEM161B-AS1 |
Ulcerative Colitis |
2.12 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
C6orf3 COMMD7 |
Blood Eosinophil Count |
5.35 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
ATXN2 NAT6 REST |
Blood Platelet Count |
0.99 |
11 |
3 |
6.7 |
-0.38 |
2.4e-01 |
ATXN2 C10orf32 COMMD7 CPSF4 MSH6 NOB1 REST STX1B TMEM161B-AS1 TMEM180 TMEM242 |
Blood Red Count |
1.75 |
6 |
4 |
8.9 |
0.19 |
7.2e-01 |
ATXN2 COMMD7 GTF3C6 MAP2K5 NAT6 RP5-1112D6.4 |
Blood White Count |
3.51 |
5 |
3 |
6.7 |
-0.93 |
2.2e-02 |
ATXN2 C10orf32 CPSF4 REST SRR |
Heel T-Score |
1.37 |
6 |
2 |
4.4 |
-0.53 |
2.8e-01 |
C10orf32 MSH6 NCAM1 NOB1 REST SRR |
BMI |
4.23 |
10 |
6 |
13.3 |
-0.45 |
1.9e-01 |
CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NOB1 NPC1 SRR STX1B TMEM161B-AS1 |
Height |
0.78 |
12 |
3 |
6.7 |
-0.17 |
6.0e-01 |
ATXN2 C10orf32 C6orf3 CCDC167 CPSF4 NAT6 NCAM1 NOB1 PRPS1P2 REST SRR TMEM180 |
Waist Hip Ratio (WHR) |
1.16 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
MSH6 NAT6 PRPS1P2 |
Systolic Blood Pressure |
2.87 |
5 |
3 |
6.7 |
0.37 |
5.4e-01 |
ATXN2 CADM2 NCAM1 NOB1 SRR |
Smoking Status |
16.16 |
23 |
17 |
37.8 |
-0.99 |
7.3e-18 |
C10orf32 C6orf3 CADM2 CCDC167 COMMD7 CPSF4 GTF3C6 KIAA1908 MAP2K5 MSH6 NAT6 NCAM1 NOB1 PRPS1P2 REST RP11-89K21.1 RP5-1112D6.4 SDK1 SRR STX1B TMEM161B-AS1 TMEM180 TMEM242 |
Allergy or Eczema |
1.92 |
5 |
0 |
0.0 |
0.69 |
1.9e-01 |
ATXN2 C10orf32 CPSF4 SRR TMEM180 |
Cardiovascular Disease |
2.46 |
4 |
2 |
4.4 |
0.00 |
1.0e+00 |
ATXN2 MAP2K5 NPC1 TMEM161B-AS1 |
Hypothyroidism (self reported) |
3.37 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ATXN2 |
Respiratory disease |
1.29 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
REST |
Type 2 Diabetes (T2D) (2018) |
1.80 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 CPSF4 |
Lung FEV1/FVC ratio |
0.87 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
COMMD7 MSH6 REST |
Lung FVC |
1.85 |
7 |
4 |
8.9 |
0.04 |
9.3e-01 |
C6orf3 MAP2K5 MSH6 NOB1 PRPS1P2 REST STX1B |
Neuroticism |
2.10 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
CADM2 MAP2K5 PRPS1P2 |
Chronotype (morning person) |
2.20 |
4 |
0 |
0.0 |
-0.02 |
9.8e-01 |
ATXN2 CPSF4 NCAM1 TMEM161B-AS1 |
Hair Pigment |
0.17 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 MSH6 REST |
Tanning |
0.73 |
4 |
1 |
2.2 |
-0.95 |
4.6e-02 |
ATXN2 CADM2 COMMD7 KIAA1908 |
Hand grip strength (left) |
3.09 |
5 |
2 |
4.4 |
-0.64 |
2.4e-01 |
C10orf32 CADM2 NOB1 PRPS1P2 TMEM180 |
Number of treatments/medications taken |
2.02 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ATXN2 COMMD7 |
Sensitivity / hurt feelings |
0.98 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PRPS1P2 |
Relative age of first facial hair |
1.61 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
NAT6 NPC1 |
Systolic blood pressure, automated reading |
2.39 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
ATXN2 SRR |
Angina |
1.38 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NOB1 |
Impedance of leg (right) |
2.57 |
10 |
4 |
8.9 |
0.21 |
5.7e-01 |
CADM2 COMMD7 CPSF4 MAP2K5 NAT6 NCAM1 NOB1 PRPS1P2 SRR TMEM161B-AS1 |
Leg fat-free mass (left) |
2.41 |
9 |
4 |
8.9 |
-0.34 |
3.7e-01 |
C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 STX1B TMEM161B-AS1 TMEM180 |
Trunk fat percentage |
2.56 |
8 |
2 |
4.4 |
-0.40 |
3.2e-01 |
C6orf3 CPSF4 GTF3C6 MAP2K5 NOB1 NPC1 STX1B TMEM161B-AS1 |
Hand grip strength (right) |
2.34 |
4 |
1 |
2.2 |
0.12 |
8.8e-01 |
CADM2 NOB1 PRPS1P2 TMEM180 |
Townsend deprivation index at recruitment |
2.62 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
MAP2K5 PRPS1P2 |
Current tobacco smoking |
4.95 |
5 |
2 |
4.4 |
-0.96 |
1.0e-02 |
C10orf32 GTF3C6 NCAM1 PRPS1P2 RP11-89K21.1 |
Maternal smoking around birth |
4.30 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 GTF3C6 RP5-1112D6.4 |
Fed-up feelings |
1.16 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 |
Taking other prescription medications |
2.48 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ATXN2 |
Age when periods started (menarche) |
2.81 |
5 |
1 |
2.2 |
0.29 |
6.4e-01 |
MAP2K5 MSH6 NAT6 NOB1 PRPS1P2 |
Heel bone mineral density (BMD) T-score, automated (left) |
1.11 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
REST |
Qualifications: CSEs or equivalent |
1.86 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
COMMD7 |
High blood pressure |
2.56 |
4 |
2 |
4.4 |
-0.79 |
2.1e-01 |
ATXN2 MAP2K5 SRR TMEM161B-AS1 |
Medication: Atenolol |
1.98 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ATXN2 |
Medication: Levothyroxine sodium |
3.07 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ATXN2 |
Sitting height |
0.82 |
5 |
0 |
0.0 |
-0.52 |
3.7e-01 |
C10orf32 CPSF4 NCAM1 PRPS1P2 TMEM180 |
Chronic bronchitis/emphysema (father) |
1.74 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MAP2K5 |
Body mass index (BMI) |
4.19 |
11 |
6 |
13.3 |
-0.53 |
9.5e-02 |
C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NOB1 NPC1 SRR STX1B TMEM161B-AS1 |
Impedance of leg (left) |
2.65 |
10 |
3 |
6.7 |
0.17 |
6.4e-01 |
CADM2 COMMD7 CPSF4 MAP2K5 NAT6 NOB1 PRPS1P2 SDK1 SRR TMEM161B-AS1 |
Leg predicted mass (left) |
2.44 |
9 |
4 |
8.9 |
-0.34 |
3.8e-01 |
C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 STX1B TMEM161B-AS1 TMEM180 |
Trunk fat mass |
2.85 |
8 |
2 |
4.4 |
-0.38 |
3.5e-01 |
C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NPC1 STX1B TMEM161B-AS1 |
Waist circumference |
3.57 |
9 |
4 |
8.9 |
-0.52 |
1.5e-01 |
C6orf3 CADM2 CPSF4 MAP2K5 NAT6 NOB1 NPC1 STX1B TMEM161B-AS1 |
Number of incorrect matches in round |
0.99 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 |
Nervous feelings |
4.08 |
5 |
1 |
2.2 |
0.82 |
9.1e-02 |
C10orf32 CADM2 PRPS1P2 SRR TMEM180 |
Hearing difficulty/problems with background noise |
2.02 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NPC1 |
Had other major operations |
1.89 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NPC1 |
Forced vital capacity (FVC) |
1.74 |
4 |
1 |
2.2 |
-0.41 |
5.9e-01 |
C10orf32 NOB1 PRPS1P2 REST |
Heel bone mineral density (BMD) T-score, automated (right) |
1.22 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
NCAM1 REST |
Qualifications: None of the above |
1.50 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NAT6 |
Mouth/teeth dental problems |
1.38 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PRPS1P2 |
Heart attack |
2.58 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 NOB1 |
Allergy |
1.34 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SRR |
Medication: Ramipril |
1.70 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 NPC1 |
Illnesses of siblings |
1.77 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 |
Neuroticism score |
1.76 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PRPS1P2 |
Weight |
3.10 |
9 |
4 |
8.9 |
-0.53 |
1.4e-01 |
C10orf32 C6orf3 CADM2 CPSF4 MAP2K5 NAT6 NPC1 STX1B TMEM161B-AS1 |
Impedance of arm (right) |
2.85 |
5 |
2 |
4.4 |
0.93 |
2.2e-02 |
CADM2 CPSF4 MAP2K5 NAT6 STX1B |
Arm fat percentage (right) |
3.30 |
11 |
3 |
6.7 |
-0.41 |
2.1e-01 |
C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NOB1 NPC1 SRR STX1B TMEM161B-AS1 |
Trunk fat-free mass |
2.05 |
9 |
4 |
8.9 |
-0.44 |
2.4e-01 |
ATXN2 C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 REST TMEM180 |
Hip circumference |
3.12 |
10 |
5 |
11.1 |
-0.40 |
2.5e-01 |
ATXN2 C10orf32 C6orf3 CADM2 CPSF4 MAP2K5 NAT6 NPC1 STX1B TMEM161B-AS1 |
Alcohol intake versus 10 years previously |
2.26 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 NPC1 |
Father's age at death |
2.12 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 CCDC167 |
Worrier / anxious feelings |
4.57 |
5 |
1 |
2.2 |
0.99 |
2.0e-03 |
C10orf32 CADM2 GTF3C6 STX1B TMEM180 |
Number of live births |
2.05 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
CADM2 NAT6 |
Forced expiratory volume in 1-second (FEV1) |
2.00 |
4 |
2 |
4.4 |
0.48 |
5.2e-01 |
NOB1 PRPS1P2 REST RP11-89K21.1 |
Pulse rate |
2.09 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NAT6 |
Qualifications: A levels/AS levels or equivalent |
1.71 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CADM2 NAT6 |
Mouth/teeth dental problems: Dentures |
1.84 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NAT6 |
Forced expiratory volume in 1-second (FEV1), Best measure |
1.60 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
NOB1 PRPS1P2 REST |
Impedance of arm (left) |
2.93 |
7 |
2 |
4.4 |
0.94 |
1.5e-03 |
CADM2 CPSF4 MAP2K5 NAT6 REST STX1B TMEM180 |
Arm fat mass (right) |
3.63 |
11 |
5 |
11.1 |
-0.47 |
1.5e-01 |
C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NOB1 NPC1 SRR STX1B TMEM161B-AS1 |
Trunk predicted mass |
2.03 |
9 |
4 |
8.9 |
-0.43 |
2.5e-01 |
ATXN2 C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 REST TMEM180 |
Standing height |
0.78 |
6 |
1 |
2.2 |
-0.15 |
7.8e-01 |
ATXN2 C10orf32 CPSF4 NCAM1 PRPS1P2 TMEM180 |
Tense / 'highly strung' |
1.36 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CADM2 |
Hair/balding pattern: Pattern 4 |
1.77 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C6orf3 MSH6 SRR |
Birth weight of first child |
1.67 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ATXN2 |
Peak expiratory flow (PEF) |
1.78 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C10orf32 PRPS1P2 REST |
Pulse wave reflection index |
2.46 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NAT6 |
Blood clot in the leg (DVT) |
1.72 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 |
Medication: Paracetamol |
1.77 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
COMMD7 |
Headache pain in last month |
1.75 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MAP2K5 |
Medication for cholesterol, blood pressure or diabetes |
2.11 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 |
Gout (self-reported) |
1.66 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 |
Hypothyroidism/myxoedema (self-reported) |
2.90 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ATXN2 |
Birth weight |
1.80 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ATXN2 SRR |
Forced vital capacity (FVC), Best measure |
1.47 |
4 |
0 |
0.0 |
0.59 |
4.1e-01 |
MSH6 NOB1 PRPS1P2 REST |
Body fat percentage |
2.96 |
7 |
2 |
4.4 |
-0.37 |
4.1e-01 |
C6orf3 CPSF4 GTF3C6 MAP2K5 NPC1 STX1B TMEM161B-AS1 |
Leg fat percentage (right) |
3.20 |
9 |
3 |
6.7 |
-0.67 |
4.7e-02 |
C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NPC1 RP5-1112D6.4 STX1B |
Arm fat-free mass (right) |
2.69 |
10 |
5 |
11.1 |
-0.47 |
1.7e-01 |
ATXN2 C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 REST STX1B TMEM180 |
Exposure to tobacco smoke outside home |
2.31 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 NAT6 |
Comparative body size at age 10 |
4.32 |
6 |
5 |
11.1 |
0.03 |
9.6e-01 |
CADM2 MAP2K5 NAT6 NPC1 SRR TMEM161B-AS1 |
Number of full brothers |
1.99 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CADM2 |
Worry too long after embarrassment |
2.42 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CADM2 MAP2K5 |
Seen a psychiatrist for nerves, anxiety, tension or depression |
1.57 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PRPS1P2 |
Number of children fathered |
2.57 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
CADM2 |
Age at first live birth |
1.68 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NAT6 |
Shortness of breath walking on level ground |
2.00 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
COMMD7 |
Qualifications: College or University degree |
2.41 |
5 |
2 |
4.4 |
0.60 |
2.9e-01 |
C10orf32 CADM2 NAT6 NPC1 SDK1 |
Mouth/teeth dental problems: Loose teeth |
1.52 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TMEM180 |
Medication for pain relief, constipation, heartburn |
2.18 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
COMMD7 |
Medication: Blood pressure |
2.26 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ATXN2 |
Angina (self-reported) |
1.33 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NOB1 |
Medication: Allopurinol |
1.63 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 |
Mean time to correctly identify matches |
2.38 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ATXN2 COMMD7 |
Whole body fat mass |
3.39 |
9 |
4 |
8.9 |
-0.47 |
2.0e-01 |
C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NPC1 STX1B TMEM161B-AS1 |
Leg fat mass (right) |
3.93 |
8 |
5 |
11.1 |
-0.66 |
7.7e-02 |
C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NPC1 STX1B |
Arm predicted mass (right) |
2.67 |
10 |
4 |
8.9 |
-0.47 |
1.7e-01 |
ATXN2 C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 REST STX1B TMEM180 |
Pulse rate, automated reading |
2.07 |
4 |
1 |
2.2 |
0.57 |
4.3e-01 |
CPSF4 MSH6 NAT6 TMEM161B-AS1 |
Alcohol intake frequency. |
3.29 |
4 |
2 |
4.4 |
0.90 |
9.5e-02 |
CADM2 NPC1 REST RP11-89K21.1 |
Comparative height size at age 10 |
0.83 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 NAT6 TMEM180 |
Number of full sisters |
2.25 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
CADM2 |
Suffer from 'nerves' |
2.65 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
CADM2 |
Overall health rating |
1.88 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
NPC1 PRPS1P2 |
Age at last live birth |
1.59 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NAT6 |
Qualifications: NVQ or HND or HNC or equivalent |
2.38 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 SDK1 |
Medication: Aspirin |
1.72 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 |
Hypertension (Self-reported) |
2.34 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ATXN2 MAP2K5 SRR |
Smoking status: Previous |
15.57 |
23 |
6 |
13.3 |
-0.99 |
8.2e-21 |
ATXN2 C10orf32 C6orf3 CADM2 CCDC167 COMMD7 GTF3C6 KIAA1908 MAP2K5 MSH6 NAT6 NCAM1 NOB1 NPC1 REST RP11-89K21.1 RP5-1112D6.4 SDK1 SRR STX1B TMEM161B-AS1 TMEM180 TMEM242 |
Forced expiratory volume in 1-second (FEV1), predicted |
0.93 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
SDK1 |
Whole body fat-free mass |
2.20 |
10 |
4 |
8.9 |
-0.44 |
2.0e-01 |
ATXN2 C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 REST STX1B TMEM180 |
Leg fat-free mass (right) |
2.23 |
9 |
3 |
6.7 |
-0.34 |
3.7e-01 |
C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 STX1B TMEM161B-AS1 TMEM180 |
Arm fat percentage (left) |
3.28 |
11 |
3 |
6.7 |
-0.41 |
2.1e-01 |
C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NOB1 NPC1 SRR STX1B TMEM161B-AS1 |
Average weekly red wine intake |
3.09 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
NPC1 |
Mood swings |
1.00 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 |
Loneliness, isolation |
1.81 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
KIAA1908 |
Long-standing illness, disability or infirmity |
3.14 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
GTF3C6 RP5-1112D6.4 |
Friendships satisfaction |
1.52 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NPC1 |
Qualifications: nursing, teaching |
1.67 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CADM2 SDK1 |
Medication for cholesterol |
1.35 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 |
Medication: Aspirin |
1.61 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 |
Illnesses of father: None of the above (group 1) |
1.46 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 |
Smoking status: Current |
5.21 |
6 |
2 |
4.4 |
-0.97 |
1.8e-03 |
C10orf32 CADM2 GTF3C6 NCAM1 PRPS1P2 RP11-89K21.1 |
Forced expiratory volume in 1-second (FEV1), predicted percentage |
2.08 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
PRPS1P2 REST STX1B |
Whole body water mass |
2.25 |
10 |
4 |
8.9 |
-0.43 |
2.1e-01 |
ATXN2 C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 REST STX1B TMEM180 |
Leg predicted mass (right) |
2.23 |
9 |
3 |
6.7 |
-0.34 |
3.7e-01 |
C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 STX1B TMEM161B-AS1 TMEM180 |
Arm fat mass (left) |
3.67 |
10 |
5 |
11.1 |
-0.55 |
1.0e-01 |
C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NOB1 NPC1 STX1B TMEM161B-AS1 |
Number of self-reported non-cancer illnesses |
2.34 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ATXN2 MAP2K5 |
Miserableness |
1.22 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NCAM1 |
Wears glasses or contact lenses |
2.22 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CADM2 NPC1 |
Commuting to job workplace: Public transport |
1.62 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CADM2 |
Eye problems/disorders: Glaucoma |
1.16 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MAP2K5 |
Medication: Blood pressure |
1.65 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
ATXN2 |
Supplements: Fish oil (including cod liver oil) |
1.42 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CPSF4 |
Medication: Bendroflumethiazide |
1.43 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 |
Medication: Paracetamol |
1.32 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
COMMD7 |
Alcohol drinker status: Never |
2.01 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CADM2 |
Ever smoked |
16.05 |
25 |
11 |
24.4 |
-0.99 |
1.8e-24 |
ATXN2 C10orf32 C6orf3 CADM2 CCDC167 COMMD7 CPSF4 GTF3C6 KIAA1908 MAP2K5 MSH6 NAT6 NCAM1 NOB1 NPC1 PRPS1P2 REST RP11-89K21.1 RP5-1112D6.4 SDK1 SRR STX1B TMEM161B-AS1 TMEM180 TMEM242 |
Basal metabolic rate |
2.43 |
9 |
5 |
11.1 |
-0.35 |
3.6e-01 |
ATXN2 C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 STX1B TMEM180 |
Leg fat percentage (left) |
3.29 |
9 |
3 |
6.7 |
-0.67 |
4.7e-02 |
C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NPC1 RP5-1112D6.4 STX1B |
Arm fat-free mass (left) |
2.73 |
10 |
4 |
8.9 |
-0.46 |
1.9e-01 |
ATXN2 C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 REST STX1B TMEM180 |
Number of operations (self-reported) |
1.33 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
NAT6 |
Average weekly beer plus cider intake |
2.82 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
CADM2 NAT6 RP11-89K21.1 |
Irritability |
1.57 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
C10orf32 |
Risk taking |
4.59 |
4 |
1 |
2.2 |
-0.95 |
5.1e-02 |
C10orf32 CADM2 RP11-89K21.1 TMEM242 |
Age started oral contraceptive pill |
2.82 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CADM2 NPC1 |
Diastolic blood pressure, automated reading |
3.41 |
4 |
2 |
4.4 |
-0.74 |
2.6e-01 |
ATXN2 C10orf32 MAP2K5 SRR |
Vascular/heart problems diagnosed by doctor |
2.83 |
4 |
2 |
4.4 |
0.85 |
1.5e-01 |
ATXN2 MAP2K5 SRR TMEM161B-AS1 |
Pain experienced in last month |
2.87 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 COMMD7 PRPS1P2 |
Heart attack/myocardial infarction (self-reported) |
2.47 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ATXN2 NOB1 |
Impedance of whole body |
2.92 |
7 |
3 |
6.7 |
0.71 |
7.4e-02 |
CADM2 CPSF4 MAP2K5 NAT6 PRPS1P2 STX1B TMEM180 |
Leg fat mass (left) |
3.93 |
9 |
5 |
11.1 |
-0.68 |
4.2e-02 |
C10orf32 C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NPC1 STX1B |
Arm predicted mass (left) |
2.75 |
10 |
4 |
8.9 |
-0.45 |
1.9e-01 |
ATXN2 C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 REST STX1B TMEM180 |